Study wrapper · #896
Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.
Au HCT, Zheng YJ, Le GH, et al. Obesity reviews. 2026.
DOI: 10.1111/obr.70120PubMed: 41792979
Editor's note
This systematic review of adverse-event reports found semaglutide and liraglutide associated with elevated reported odds of suicidal ideation, with tirzepatide showing a nonsignificant trend. Both tracked peptides are genuine subjects and the safety topic is important. Critically, the data are disproportionality signals from spontaneous reports and the authors state no causality is apparent, so this is a hypothesis, not a confirmed risk.
Plain-language abstract
A systematic review of pharmacovigilance reports found semaglutide and liraglutide associated with higher reported odds of suicidal ideation, though the authors found no evidence of a causal link.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026